Author(s):
Israa Burhan Raoof, Mayssaa E. Abdalah, Raghad Abdulmahdi Mohsin
Email(s):
israaburhan@uomustansiriyah.edu.iq
DOI:
10.52711/0974-360X.2022.00516 
Address:
Israa Burhan Raoof, Mayssaa E. Abdalah, Raghad Abdulmahdi Mohsin
Department of Clinical Laboratory Science, Department of Clinical Laboratory Science, Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad – Iraq.
*Corresponding Author
Published In:
Volume - 15,
Issue - 7,
Year - 2022
ABSTRACT:
Cholestasis defined as distortion of bile duct formation or outflow. hepatic cytotoxicity, fibrosis and biliary sclerosis are the main complications of liver disease. Recently found that significant relationship between cholestasis and vitamin D3 therefore many studies demonstrate that vit.D3 deficiencies may develop to osteomalacia especially in bile duct obstruction. The results were included different parameters like (ALT, AST, ALK.P, TSB and Vit.D3)., also different distributions of patients for examples hypertension, dyslipidaemia, myocardial Infraction and smoking, the results appeared increased significant value (p<0.05) of weight, systolic and diastolic except height, there was decreased level while no significant (p>0.05) of Age in patients as compared with control groups also there was increased significant value (p<0.05) in each of Alanine Transferase (ALT), Alkaline Phosphatase (ALK.P), Total Serum Bilirubin (TSB) except Vit.D3 there was decreased level while no significant (p>0.05) of Aspartate Transferase (AST) in patients as compared with control groups. Receiver operator curve (ROC) analysis of ALK.P and Vit.D3 is determined acceptable values of sensitivity and specificity. Also boxplot graphs expressed by Statistical Packages for Social Sciences-version used to compare between patients and healthy subjects.
Cite this article:
Israa Burhan Raoof, Mayssaa E. Abdalah, Raghad Abdulmahdi Mohsin. Relation between Vit. D3 and other Metabolic Risk Factors in patients with Cholestatic Liver Disease. Research Journal of Pharmacy and Technology. 2022; 15(7):3086-0. doi: 10.52711/0974-360X.2022.00516
Cite(Electronic):
Israa Burhan Raoof, Mayssaa E. Abdalah, Raghad Abdulmahdi Mohsin. Relation between Vit. D3 and other Metabolic Risk Factors in patients with Cholestatic Liver Disease. Research Journal of Pharmacy and Technology. 2022; 15(7):3086-0. doi: 10.52711/0974-360X.2022.00516 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-7-38
REFERENCES:
1. Subin M. Aleykutty N. Vidya V. Halima O.A. An Overview on Hepatoprotective Activity of Natural Products. Research J. Pharm. and Tech. 2012; 5(3):317-321.
2. Nur Q. Gayathri R. Fatty Liver Disease - A Review. Research J. Pharm. and Tech.2016; 9(8):1263-1267. DOI: 10.5958/0974-360X.2016.00240.7
3. Choudhari S. Jothipriya A. Non-alcoholic fatty liver disease. Research J. Pharm. and Tech. 2016; 9(10): 1782-1785. DOI: 10.5958/0974-360X.2016.00360.7
4. Affrin J. H. Savitha G. Serum Gamma Glutamyl Transferase Activity in Liver Diseases. Research J. Pharm. and Tech. 2018; 11(1):11-70.
5. Ajmer Singh Grewal, Komal Thapa, Anil Bansal, Deepshikha, Neelam Sharma, Sukhbir Singh. Therapeutic role of nuclear factor erythroid-2 related factor 2 (Nrf2) in liver disorders Research J. Pharm. and Tech.2020; 13(8): 3952-3956. DOI: 10.5958/0974-360X.2020.00699.X
6. Thaminee S. Prednisolone in Alcoholic Liver Disorder. Research J. Pharm. and Tech. 2016; 9(10): 2041-2042. DOI: 10.5958/0974-360X.2016.00417.0
7. Subashree R. Radhika A. Vitamin D Deficiency in Periodontal Health. Research J. Pharm. and Tech. 2014; 7(2): 248-252.
8. Rajalakshimi V. Vijey A. Hypovitaminosis D Influences Chronic Ailments; Implication for Health Research J. Pharm. and Tech. 2018; 11(6): 2659-2666. DOI: 10.5958/0974-360X.2018.00493.6
9. Nawazish A. Om P. et al. Natural Immunoenhancers. Research J. Pharm. and Tech. 2011; 4(10): 1526-1532
10. Harini K. Vishnu P. Gayathri R. Awareness of Importance of Vitamin D Among Dental Students in a Dental School – A Survey. 2016; 9(8): 8-24. DOI: 10.5958/0974-360X.2016.00215.8
11. Galia P. Gerald Y. Diagnostic considerations for cholestatic liver disease. Journal of Gastroenterology and Hepatology. 2017; 32 (7):1303–1309. DOI: 10.1111/jgh.13738
12. Elsemieke d. Ulrich B. Management of cholestatic disease in 2017. Liver International. 2017; 37(1): 123–129. Doi: 10.1111/liv.13306.
13. Eleanna T. et al. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. Redox Report. 2015; 20 (1): 33-41. Doi: 10.1179/1351000214Y.0000000101
14. Walid M. Dina H. Rania G. Ahmed O. Suzan B. Berihan R. The impact of total bile acid levels on fetal cardiac function in intrahepatic cholestasis of pregnancy using fetal echocardiography: A tissue Doppler imaging study. J Matern Fetal Neonatal Med. 2016; 29(9):1–6. Doi: 10.3109/14767058.2015.1051020.
15. Boonstra K. Weersma R. Erpecum K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013; 58(6):2045–2055. Doi: 10.1002/hep.26565.
16. Camilleri M. Gores G. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015; 309(4): 209‐215. Doi: 10.1152/ajpgi.00121.
17. Andrei V. et al. Bile acids and cardiovascular function in cirrhosis. Liver International. 2017; 37(10):1420–1430. Doi: 10.1111/liv.13394.
18. Ioana M. Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015; 8: 7(4): 662-672. Doi: 10.4254/wjh.v7.i4.662
19. Manal M. Ahmed E. Dalia S. Khaled K. Association between vitamin D level and patients with cholestasis: Int J Community Med Public Health. 2018; 5(5):1713-171. DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20181675
20. Emre C. Baris B. Hatice A. Mustafa B. Cagri G. et al. Vitamin D Levels in Women with Intrahepatic Cholestasis of Pregnancy: Insights Biomed Res.2017; 1(1):1-4. DOI: 10.36959/584/436.
21. Yusuke K. Mutsumi M. Atsuhiro N. Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody. PLoS One: 2015; 10(9):1-16. Doi: 10.1371/journal.pone.0139620
22. Philip N. Newsome et al. Guidelines on the management of abnormal liver blood tests. Gut: 2018; 67(1): 6-19. Doi: 10.1136/gutjnl-2017-314924.
23. Wen X. Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Scientific Reports. 2017; 7(1):1-7. DOI: 10.1038/s41598-017-11111-5
24. Paul Y.ACG Practice Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017; 112(1):18-35. Doi: 10.1038/ajg.2016.517
25. Rui D. Song S. Xiao-Z. Zhen S. Gong C. Sha Z. Fat-Soluble Vitamin Deficiency in Pediatric Patients with Biliary Atresia. Gastroenterology Research and Practice: 2017(3):1-8. DOI: 10.1155/2017/7496860
26. Jeremy T. et al. Vitamin D and the Liver-Correlation or Cause? Nutrients. 2018; 10 (496):1-19. Doi: 10.3390/nu10040496